You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAgomelatine
Accession NumberDB06594
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionAgomelatine is structurally closely related to melatonin. Agomelatine is a potent agonist at melatonin receptors and an antagonist at serotonin-2C (5-HT2C) receptors, tested in an animal model of depression. Agomelatine was discovered and developed by the European pharmaceutical company Servier Laboratories Ltd. Servier continue to develop the drug and conduct phase III trials in the European Union. In 2005 Servier submitted Agomelatine to the European Medicines Agency (EMEA). On 27 July 2006 the Committee for Medical Products for Human Use (CHMP) of the EMEA recommended a refusal of the marketing authorisation of Valdoxan/Thymanax. The major concern was that efficacy had not been sufficiently shown. In 2006 Servier sold the rights to develop Agomelatine in the US to Novartis. The development for the US market was discontinued in October 2011. It is currently sold in Australia under the Valdoxan trade name.
Structure
Thumb
Synonyms
Valdoxan
External Identifiers
  • S-20098
  • S20098
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
MelitorServier Laboratories Ltd.
ValdoxanServier Laboratories Ltd.
Brand mixturesNot Available
SaltsNot Available
Categories
UNII137R1N49AD
CAS number138112-76-2
WeightAverage: 243.301
Monoisotopic: 243.125928793
Chemical FormulaC15H17NO2
InChI KeyInChIKey=YJYPHIXNFHFHND-UHFFFAOYSA-N
InChI
InChI=1S/C15H17NO2/c1-11(17)16-9-8-13-5-3-4-12-6-7-14(18-2)10-15(12)13/h3-7,10H,8-9H2,1-2H3,(H,16,17)
IUPAC Name
N-[2-(7-methoxynaphthalen-1-yl)ethyl]acetamide
SMILES
COC1=CC2=C(C=CC=C2CCNC(C)=O)C=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as naphthalenes. These are compounds containing a naphthalene moiety, which consists of two fused benzene rings.
KingdomOrganic compounds
Super ClassBenzenoids
ClassNaphthalenes
Sub ClassNot Available
Direct ParentNaphthalenes
Alternative Parents
Substituents
  • Naphthalene
  • Phenethylamine
  • Anisole
  • Alkyl aryl ether
  • Acetamide
  • Secondary carboxylic acid amide
  • Carboxamide group
  • Ether
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aromatic homopolycyclic compound
Molecular FrameworkAromatic homopolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationAgomelatine is indicated for the treatment of major depressive episodes in adults.
PharmacodynamicsAgomelatine resynchronises circadian rhythms in animal models of delayed sleep phase syndrome and other circadian rhythm disruptions. It increases noradrenaline and dopamine release specifically in the frontal cortex and has no influence on the extracellular levels of serotonin. Agomelatine has shown an antidepressant-like effect in animal models of depression (learned helplessness test, despair test, chronic mild stress) as well as in models with circadian rhythm desynchronisation and in models related to stress and anxiety. In humans, agomelatine has positive phase shifting properties; it induces a phase advance of sleep, body temperature decline and melatonin onset. Controlled studies in humans have shown that agomelatine is as effective as the SSRI antidepressants paroxetine and sertraline in the treatment of major depression
Mechanism of actionThe novel antidepressant agent, agomelatine, behaves as an agonist at melatonin receptors (MT1 and MT2) and as an antagonist at serotonin (5-HT)(2C) receptors.
Related Articles
AbsorptionBioavailability is less than 5%.
Volume of distributionNot Available
Protein binding> 95%
Metabolism

Hepatic (90% CYP1A2 and 10% CYP2C9).

Route of eliminationNot Available
Half life<2 hours
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9923
Caco-2 permeable+0.7464
P-glycoprotein substrateSubstrate0.5356
P-glycoprotein inhibitor INon-inhibitor0.6423
P-glycoprotein inhibitor IINon-inhibitor0.6412
Renal organic cation transporterNon-inhibitor0.5291
CYP450 2C9 substrateNon-substrate0.7647
CYP450 2D6 substrateSubstrate0.7219
CYP450 3A4 substrateSubstrate0.7276
CYP450 1A2 substrateInhibitor0.8543
CYP450 2C9 inhibitorNon-inhibitor0.7758
CYP450 2D6 inhibitorNon-inhibitor0.5445
CYP450 2C19 inhibitorNon-inhibitor0.7478
CYP450 3A4 inhibitorNon-inhibitor0.7746
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5467
Ames testAMES toxic0.6796
CarcinogenicityNon-carcinogens0.8958
BiodegradationNot ready biodegradable0.8296
Rat acute toxicity2.2095 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9236
hERG inhibition (predictor II)Inhibitor0.6648
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubility~0.5 mg/ml in 1:1 EtOH:PBS (pH 7.2); ~30 mg/ml in EtOH, DMF & DMSONot Available
Predicted Properties
PropertyValueSource
Water Solubility0.00776 mg/mLALOGPS
logP2.83ALOGPS
logP2.04ChemAxon
logS-4.5ALOGPS
pKa (Strongest Acidic)15.96ChemAxon
pKa (Strongest Basic)-0.94ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area38.33 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity71.64 m3·mol-1ChemAxon
Polarizability27.18 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Jean-Claude Souvie, Isaac Gonzalez Blanco, Gilles Thominot, Genevieve Chapuis, Stephane Horvath, Gerard Damien, “Process for the synthesis and crystalline form of agomelatine.” U.S. Patent US20050182276, issued August 18, 2005.

US20050182276
General References
  1. Millan MJ, Brocco M, Gobert A, Dekeyne A: Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade. Psychopharmacology (Berl). 2005 Feb;177(4):448-58. Epub 2004 Jul 31. [PubMed:15289999 ]
  2. Hardeland R, Poeggeler B, Srinivasan V, Trakht I, Pandi-Perumal SR, Cardinali DP: Melatonergic drugs in clinical practice. Arzneimittelforschung. 2008;58(1):1-10. doi: 10.1055/s-0031-1296459. [PubMed:18368944 ]
  3. Racagni G, Riva MA, Popoli M: The interaction between the internal clock and antidepressant efficacy. Int Clin Psychopharmacol. 2007 Oct;22 Suppl 2:S9-S14. [PubMed:17917564 ]
External Links
ATC CodesN06AX22
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (15.5 KB)
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Agomelatine.
AbirateroneThe serum concentration of Agomelatine can be increased when it is combined with Abiraterone.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Agomelatine.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Agomelatine.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Agomelatine is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Agomelatine.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Agomelatine.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Agomelatine.
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Agomelatine.
AmitriptylineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Amitriptyline.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Agomelatine.
AmoxapineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Agomelatine is combined with Amperozide.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Agomelatine.
ArticaineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Agomelatine.
AzaperoneThe risk or severity of adverse effects can be increased when Agomelatine is combined with Azaperone.
AzelastineAgomelatine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Agomelatine.
AzithromycinThe serum concentration of Agomelatine can be increased when it is combined with Azithromycin.
BaclofenThe risk or severity of adverse effects can be increased when Agomelatine is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Agomelatine.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Agomelatine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Agomelatine is combined with Benzyl alcohol.
BortezomibThe serum concentration of Agomelatine can be increased when it is combined with Bortezomib.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Agomelatine is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Agomelatine.
BrimonidineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Agomelatine.
BrompheniramineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Agomelatine is combined with Brotizolam.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Agomelatine.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Agomelatine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Agomelatine.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Agomelatine.
ButacaineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Agomelatine is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Agomelatine is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Agomelatine.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Agomelatine.
CaffeineThe serum concentration of Agomelatine can be increased when it is combined with Caffeine.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Agomelatine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Agomelatine.
CarisoprodolThe risk or severity of adverse effects can be increased when Agomelatine is combined with Carisoprodol.
CetirizineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Agomelatine.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Agomelatine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Agomelatine.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Agomelatine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Chlorphenamine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Agomelatine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Agomelatine.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Agomelatine is combined with Chlorzoxazone.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Agomelatine.
CitalopramThe serum concentration of Agomelatine can be increased when it is combined with Citalopram.
CitalopramThe risk or severity of adverse effects can be increased when Agomelatine is combined with Citalopram.
ClemastineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Agomelatine is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Agomelatine is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Agomelatine.
ClomipramineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Agomelatine is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Agomelatine.
ClotrimazoleThe serum concentration of Agomelatine can be increased when it is combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Agomelatine.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Agomelatine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Agomelatine.
CyclizineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Agomelatine.
CyproheptadineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Cyproheptadine.
DantroleneThe risk or severity of adverse effects can be increased when Agomelatine is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Agomelatine.
DapoxetineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Dapoxetine.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Agomelatine.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Agomelatine.
DesipramineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Detomidine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Agomelatine.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Agomelatine.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Agomelatine.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Agomelatine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Agomelatine.
DifenoxinThe risk or severity of adverse effects can be increased when Agomelatine is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Agomelatine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Agomelatine.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Agomelatine.
DimenhydrinateThe risk or severity of adverse effects can be increased when Agomelatine is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Agomelatine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Agomelatine.
DoramectinThe risk or severity of adverse effects can be increased when Agomelatine is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Agomelatine is combined with Doxepin.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Agomelatine.
DoxylamineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Agomelatine is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Agomelatine.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Agomelatine.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Agomelatine.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Agomelatine.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Agomelatine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Agomelatine.
EfavirenzThe risk or severity of adverse effects can be increased when Agomelatine is combined with Efavirenz.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Agomelatine.
EntacaponeThe risk or severity of adverse effects can be increased when Agomelatine is combined with Entacapone.
EscitalopramThe risk or severity of adverse effects can be increased when Agomelatine is combined with Escitalopram.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Agomelatine.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Agomelatine.
EthanolAgomelatine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Agomelatine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Agomelatine.
EthosuximideThe risk or severity of adverse effects can be increased when Agomelatine is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Agomelatine is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Agomelatine.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Agomelatine.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Agomelatine.
EtidocaineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Agomelatine is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Agomelatine.
EtoperidoneThe risk or severity of adverse effects can be increased when Agomelatine is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Agomelatine.
EzogabineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Agomelatine is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Agomelatine.
FenfluramineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Agomelatine.
FexofenadineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Agomelatine is combined with Flibanserin.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Agomelatine.
FlunarizineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Agomelatine.
FluoxetineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Agomelatine.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Agomelatine.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Agomelatine.
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Agomelatine.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Agomelatine is combined with Fluticasone Propionate.
FluvoxamineThe serum concentration of Agomelatine can be increased when it is combined with Fluvoxamine.
FluvoxamineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Fluvoxamine.
FosphenytoinThe risk or severity of adverse effects can be increased when Agomelatine is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Agomelatine is combined with Fospropofol.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Agomelatine.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Agomelatine is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Agomelatine.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Agomelatine.
GuanfacineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Agomelatine.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Agomelatine.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Agomelatine.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Agomelatine.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Agomelatine.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Agomelatine.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Agomelatine.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Agomelatine.
HydroxyzineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Hydroxyzine.
IloperidoneThe risk or severity of adverse effects can be increased when Agomelatine is combined with Iloperidone.
ImipramineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Imipramine.
IndalpineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Indalpine.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Agomelatine.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Agomelatine.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Agomelatine.
KetobemidoneThe risk or severity of adverse effects can be increased when Agomelatine is combined with Ketobemidone.
LamotrigineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Lamotrigine.
LevetiracetamThe risk or severity of adverse effects can be increased when Agomelatine is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Agomelatine.
LevocabastineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Agomelatine is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Agomelatine.
LevomilnacipranThe risk or severity of adverse effects can be increased when Agomelatine is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Agomelatine.
LidocaineThe serum concentration of Agomelatine can be increased when it is combined with Lidocaine.
LidocaineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Lidocaine.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Agomelatine.
LofentanilThe risk or severity of adverse effects can be increased when Agomelatine is combined with Lofentanil.
LoratadineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Agomelatine.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Agomelatine.
Lu AA21004The risk or severity of adverse effects can be increased when Agomelatine is combined with Lu AA21004.
LurasidoneThe risk or severity of adverse effects can be increased when Agomelatine is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Agomelatine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Agomelatine is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Maprotiline.
MeclizineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Agomelatine.
MelperoneThe risk or severity of adverse effects can be increased when Agomelatine is combined with Melperone.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Agomelatine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Agomelatine.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Agomelatine.
MetaxaloneThe risk or severity of adverse effects can be increased when Agomelatine is combined with Metaxalone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Agomelatine.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Agomelatine.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Agomelatine.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Agomelatine.
MethocarbamolThe risk or severity of adverse effects can be increased when Agomelatine is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Agomelatine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Agomelatine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Agomelatine.
MethsuximideThe risk or severity of adverse effects can be increased when Agomelatine is combined with Methsuximide.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Agomelatine.
MetyrosineAgomelatine may increase the sedative activities of Metyrosine.
MexiletineThe serum concentration of Agomelatine can be increased when it is combined with Mexiletine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Agomelatine.
MilnacipranThe risk or severity of adverse effects can be increased when Agomelatine is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Agomelatine.
MirtazapineAgomelatine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Agomelatine.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Agomelatine.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Agomelatine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Agomelatine.
NabiloneThe risk or severity of adverse effects can be increased when Agomelatine is combined with Nabilone.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Agomelatine.
NevirapineThe serum concentration of Agomelatine can be increased when it is combined with Nevirapine.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Agomelatine.
Nitrous oxideThe risk or severity of adverse effects can be increased when Agomelatine is combined with Nitrous oxide.
NormethadoneThe risk or severity of adverse effects can be increased when Agomelatine is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Nortriptyline.
OlanzapineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Olanzapine.
OlopatadineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Olopatadine.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Agomelatine.
OpiumThe risk or severity of adverse effects can be increased when Agomelatine is combined with Opium.
OrphenadrineAgomelatine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Agomelatine.
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Agomelatine.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Agomelatine.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Agomelatine.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Agomelatine.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Agomelatine.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Agomelatine.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Agomelatine.
ParaldehydeAgomelatine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Agomelatine.
ParoxetineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Paroxetine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Agomelatine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Agomelatine.
PerampanelThe risk or severity of adverse effects can be increased when Agomelatine is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Agomelatine is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Agomelatine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Agomelatine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Agomelatine.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Agomelatine is combined with Phenoxyethanol.
PhenytoinThe risk or severity of adverse effects can be increased when Agomelatine is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Agomelatine.
PipamperoneThe risk or severity of adverse effects can be increased when Agomelatine is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Agomelatine is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Agomelatine is combined with Pomalidomide.
PramipexoleAgomelatine may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Agomelatine.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Agomelatine.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Agomelatine.
PrimidoneThe risk or severity of adverse effects can be increased when Agomelatine is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Agomelatine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Agomelatine.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Agomelatine.
PromethazineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Promethazine.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Agomelatine.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Agomelatine.
PropoxycaineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Propoxycaine.
ProtriptylineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Agomelatine is combined with PSD502.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Agomelatine.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Agomelatine.
RamelteonThe risk or severity of adverse effects can be increased when Agomelatine is combined with Ramelteon.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Agomelatine.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Agomelatine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Agomelatine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Agomelatine.
RomifidineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Romifidine.
RopiniroleAgomelatine may increase the sedative activities of Ropinirole.
RopiniroleThe serum concentration of Agomelatine can be increased when it is combined with Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Agomelatine.
RotigotineAgomelatine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Agomelatine.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Agomelatine.
ScopolamineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Agomelatine.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Agomelatine.
SertralineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Agomelatine.
SimeprevirThe serum concentration of Agomelatine can be increased when it is combined with Simeprevir.
Sodium oxybateThe risk or severity of adverse effects can be increased when Agomelatine is combined with Sodium oxybate.
StiripentolThe risk or severity of adverse effects can be increased when Agomelatine is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Agomelatine.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Agomelatine.
SuvorexantThe risk or severity of adverse effects can be increased when Agomelatine is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Agomelatine is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Agomelatine is combined with Tasimelteon.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Agomelatine.
TenofovirThe serum concentration of Agomelatine can be increased when it is combined with Tenofovir.
TetrabenazineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Agomelatine.
ThalidomideAgomelatine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Agomelatine.
TheophyllineThe serum concentration of Agomelatine can be increased when it is combined with Theophylline.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Agomelatine.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Agomelatine.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Agomelatine.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Agomelatine.
TiagabineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Tiagabine.
TiclopidineThe serum concentration of Agomelatine can be increased when it is combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Tiletamine.
TizanidineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Tizanidine.
TolcaponeThe risk or severity of adverse effects can be increased when Agomelatine is combined with Tolcapone.
TopiramateThe risk or severity of adverse effects can be increased when Agomelatine is combined with Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Agomelatine.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Agomelatine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Agomelatine.
TrazodoneThe risk or severity of adverse effects can be increased when Agomelatine is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Agomelatine.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Agomelatine.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Agomelatine.
TrimipramineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Triprolidine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Agomelatine.
VigabatrinThe risk or severity of adverse effects can be increased when Agomelatine is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Agomelatine is combined with Vilazodone.
VortioxetineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Xylazine.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Agomelatine.
ZiconotideThe risk or severity of adverse effects can be increased when Agomelatine is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Agomelatine.
ZolazepamThe risk or severity of adverse effects can be increased when Agomelatine is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Agomelatine.
ZonisamideThe risk or severity of adverse effects can be increased when Agomelatine is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Agomelatine.
ZotepineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Agomelatine.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
HTR2C
Uniprot ID:
P28335
Molecular Weight:
51820.705 Da
References
  1. Millan MJ, Brocco M, Gobert A, Dekeyne A: Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade. Psychopharmacology (Berl). 2005 Feb;177(4):448-58. Epub 2004 Jul 31. [PubMed:15289999 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Organic cyclic compound binding
Specific Function:
High affinity receptor for melatonin. Likely to mediates the reproductive and circadian actions of melatonin. The activity of this receptor is mediated by pertussis toxin sensitive G proteins that inhibit adenylate cyclase activity.
Gene Name:
MTNR1A
Uniprot ID:
P48039
Molecular Weight:
39374.315 Da
References
  1. Millan MJ, Brocco M, Gobert A, Dekeyne A: Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade. Psychopharmacology (Berl). 2005 Feb;177(4):448-58. Epub 2004 Jul 31. [PubMed:15289999 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Melatonin receptor activity
Specific Function:
High affinity receptor for melatonin. Likely to mediates the reproductive and circadian actions of melatonin. The activity of this receptor is mediated by pertussis toxin sensitive G proteins that inhibit adenylate cyclase activity.
Gene Name:
MTNR1B
Uniprot ID:
P49286
Molecular Weight:
40187.895 Da
References
  1. Millan MJ, Brocco M, Gobert A, Dekeyne A: Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade. Psychopharmacology (Berl). 2005 Feb;177(4):448-58. Epub 2004 Jul 31. [PubMed:15289999 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Carney RM, Shelton RC: Agomelatine for the treatment of major depressive disorder. Expert Opin Pharmacother. 2011 Oct;12(15):2411-9. doi: 10.1517/14656566.2011.607812. [PubMed:21916789 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Dolder CR, Nelson M, Snider M: Agomelatine treatment of major depressive disorder. Ann Pharmacother. 2008 Dec;42(12):1822-31. doi: 10.1345/aph.1L296. Epub 2008 Nov 25. [PubMed:19033480 ]
Comments
comments powered by Disqus
Drug created on March 19, 2008 10:39 / Updated on August 17, 2016 12:24